$25.39 Million in Sales Expected for Spark Therapeutics Inc (NASDAQ:ONCE) This Quarter

Equities analysts expect Spark Therapeutics Inc (NASDAQ:ONCE) to announce sales of $25.39 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Spark Therapeutics’ earnings. The highest sales estimate is $32.97 million and the lowest is $17.80 million. Spark Therapeutics reported sales of $10.71 million during the same quarter last year, which indicates a positive year over year growth rate of 137.1%. The company is scheduled to announce its next quarterly earnings results on Tuesday, November 19th.

According to Zacks, analysts expect that Spark Therapeutics will report full year sales of $105.53 million for the current fiscal year, with estimates ranging from $70.00 million to $125.90 million. For the next financial year, analysts forecast that the business will post sales of $132.64 million, with estimates ranging from $124.00 million to $141.27 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Spark Therapeutics.

Several equities analysts have commented on ONCE shares. ValuEngine upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Zacks Investment Research lowered shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 14th. Finally, Mizuho reiterated a “hold” rating and set a $114.50 price objective on shares of Spark Therapeutics in a research report on Monday, August 12th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $106.00.

ONCE stock traded up $0.18 during trading on Friday, hitting $111.33. 306,648 shares of the company’s stock traded hands, compared to its average volume of 921,497. Spark Therapeutics has a 52 week low of $34.53 and a 52 week high of $114.20. The company has a debt-to-equity ratio of 0.35, a quick ratio of 4.35 and a current ratio of 4.67. The business has a fifty day simple moving average of $104.40 and a 200 day simple moving average of $103.07. The stock has a market capitalization of $4.27 billion, a price-to-earnings ratio of -52.74 and a beta of 2.08.

A number of hedge funds have recently added to or reduced their stakes in ONCE. Prudential Financial Inc. raised its stake in shares of Spark Therapeutics by 11.7% in the second quarter. Prudential Financial Inc. now owns 3,430 shares of the biotechnology company’s stock valued at $351,000 after acquiring an additional 358 shares during the period. California Public Employees Retirement System raised its stake in shares of Spark Therapeutics by 0.7% in the second quarter. California Public Employees Retirement System now owns 60,782 shares of the biotechnology company’s stock valued at $6,223,000 after acquiring an additional 400 shares during the period. United Services Automobile Association raised its stake in shares of Spark Therapeutics by 9.4% in the second quarter. United Services Automobile Association now owns 5,529 shares of the biotechnology company’s stock valued at $566,000 after acquiring an additional 473 shares during the period. Tower Research Capital LLC TRC increased its stake in Spark Therapeutics by 4,568.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 887 shares of the biotechnology company’s stock worth $86,000 after buying an additional 868 shares during the period. Finally, Syquant Capital Sas increased its stake in Spark Therapeutics by 5.1% in the 3rd quarter. Syquant Capital Sas now owns 20,587 shares of the biotechnology company’s stock worth $1,997,000 after buying an additional 1,000 shares during the period. Institutional investors and hedge funds own 85.85% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

See Also: What is the Quick Ratio?

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.